Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Highest Response Rate to Date in mRCC With Pazopanib as Third-Line VEGF Inhibitor

TOP - October 2014, Vol 7, No 4 - Genitourinary Cancers
Charles Bankhead

Almost 50% of patients with metastatic renal cell carcinoma (mRCC) had objective responses to third-line treatment with the angiogenesis inhibitor pazopanib, according to the results from a small clinical trial reported at the 2014 American Association for Cancer Research annual meeting.

Overall, 12 of 28 patients achieved objective responses (including 1 complete response), and another patient had an unconfirmed partial response. In the subgroup of responding patients, the duration of response to pazopa­nib exceeded the duration of previous responses in a majority of cases.

The cohort had a median progression-free survival of 16.5 months, a “remarkable” clinical outcome for such a heavily pretreated group of patients, said principal investigator Sumanta K. Pal, MD, assistant professor of medical oncology and therapeutics research at City of Hope, Duarte, California.

“This is the highest objective response rate observed to date in a trial of third-line therapy for metastatic renal cell carcinoma,” said Pal. “Equally unprecedented is the median progression-free survival, which is remarkable for this group of patients.”

Pazopanib, a multitargeted tyrosine kinase inhibitor, is approved for the treatment of advanced RCC. Previous studies of the agent included a phase 3 trial of patients who were refractory to cytokine therapy or were treatment naive. No previous trial had determined pazopanib’s activity in the third-line setting or examined temporal changes in molecular profile during therapy.

Study Details
Pal and colleagues evaluated pazopa­nib’s third-line potential for mRCC in a well-defined group of previously treated patients. They performed a phase 3, single-arm trial involving patients whose disease had progressed after 2 previous systemic regimens, 1 of which had to be an inhibitor of vascular endothelial growth factor (VEGF). Other eligibility criteria included Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and clear cell histology.

The primary outcome was response rate, and the trial was statistically powered to detect a 23% overall response rate, defined as “clinically encouraging.” Investigators also examined immunologic markers associated with treatment failure or success.

Patients received pazopanib 800 mg daily on 28-day cycles. Treatment continued until disease progression, unacceptable toxicity, or death.

None of the patients enrolled in the study had good-risk characteristics. Approximately 60% had intermediate-risk features, and approximately 40% had poor-risk features.

Overall, 23 of the 28 patients received anti-VEGF therapy as first-line treatment, and the most frequently used second-line therapy was the mammalian target of rapamycin (mTOR) inhibitor class. Some of the patients received anti-VEGF therapy as first- and second-line therapy. The median duration of previous anti-VEGF therapy was 4 months.

In addition to the 13 patients who had responses (including the 1 unconfirmed response), 9 had stable disease, resulting in a clinical benefit rate of 78%. After a median follow-up of 17.1 months, the median overall survival had yet to be reached.

Biomarker analysis showed that response was associated with lower levels of hepatocyte growth factor, VEGF, interleukin (IL)-8, IL-6, and soluble IL-2 receptor (P <.05 for each analysis).

The most frequently reported adverse event was hypertension (93%, all grades), which was grade 3/4 in 50% of the cases. Blood pressure was manageable with antihypertensive medications, and no patient stopped treatment because of uncontrolled blood pressure. In addition, 14% of patients had grade 3 proteinuria. The most frequently reported laboratory abnormalities were hyponatremia and elevated creatinine.




Reference
Pal SK, Hossain DMS, Zhang Q, et al. Pazopanib as third-line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile. Presented at: 2014 Annual Meeting of the American Association for Cancer Research; April 5-9, 2014; San Diego, California. Abstract CT334.

Related Items
Nivolumab Shows Durable Activity in Subgroups of Patients with Metastatic CRC
Charles Bankhead
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Colorectal Cancer
Immunotherapy plus Targeted Therapy Combination Active in Metastatic CRC
Charles Bankhead
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
Addressing the Second Victim Phenomenon
Charles Bankhead
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
Nivolumab Shows Durable Activity in Subgroups of Patients with Metastatic CRC
Charles Bankhead
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Immunotherapy
Adjuvant Chemotherapy in Upper-Tract Urothelial Cancer Shows Impressive Gains in the POUT Trial
Phoebe Starr
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in Genitourinary Cancers
Mogamulizumab, Anti-CCR4 Antibody, Improves Survival in Patients with Advanced Cutaneous T-Cell Lymphoma
Charles Bankhead
Web Exclusives published on April 9, 2018 in Emerging Therapies
New BTK Inhibitor Leads to Durable Responses in Relapsed or Refractory Chronic Lymphocytic Leukemia
Charles Bankhead
Web Exclusives published on April 9, 2018 in Leukemia
High Response Rate with 3-Drug Combination for Untreated Follicular Lymphoma
Charles Bankhead
Web Exclusives published on April 9, 2018 in Lymphoma
Hormonal Therapy Associated with Anxiety in Men with Localized Prostate Cancer
Phoebe Starr
TON - May 2017, Vol 10, No 3 published on May 17, 2017 in Genitourinary Cancers
Chemotherapy Use in Breast Cancer Declines with Use of MammaPrint Gene-Based Assay
Charles Bankhead
TON - November 2016, Vol 9, No 6 published on November 15, 2016 in Breast Cancer
Last modified: May 21, 2015